Sai Parenterals Reports Robust Q2FY27 Results and Advances Major Expansion Capex
Sai Parenterals Ltd 路 Investor Presentation 路 02 Nov 2026, 1:43 am
Sai Parenterals Reports Robust Q2FY27 Results and Advances Major Expansion Capex Sai Parenterals delivered Q2FY27 consolidated revenue of Rs. 196.1 cr (up 9.0% QoQ, 257.4% YoY) with EBITDA surging 67.4% QoQ to Rs. 41.4 cr and PAT reaching Rs. 10.5 cr. H1FY27 revenue hit Rs. 376.0 cr against its full-year FY27 target of Rs. 750 cr. The company completed acquisitions of 60% stakes in Saicriti Pharma (Rs. 83.83 cr) and Sai Prathyak Laboratories (Rs. 15.0 cr) on 5th Oct'26, utilizing reallocated IPO proceeds. Ongoing Rs. 571 cr group capex remains on track, targeting EU-GMP/USFDA-ready injectable scale by Jul'27.
Original exchange filing (PDF)
More announcements from Sai Parenterals Ltd
- Press Release by Sai Parenteral''s Limited 路 17 Nov 2026
- Outcome of Board Meeting held on Monday, 16th November, 2026 路 17 Nov 2026
- call conducted on Monday the 2nd day of November, 2026. 路 07 Nov 2026
- Audio recording of earning call held on 2nd November, 2026 over call. 路 03 Nov 2026
- Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026. 路 01 Nov 2026
- Statement of variation and deviation for the period ended 30th September, 2026 路 01 Nov 2026
- Financial Results 路 01 Nov 2026
- Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 01 Nov 2026
